Skip to content
Home
Close Home
Open Home
Journal information
Editorial board
Operations manual
Editorial policies
Code of conduct for authors
Code of conduct for reviewers
Ahead of print
Read
Close Read
Open Read
Archive
TOC Alert
Current issue
Information
Close Information
Open Information
Editorial & Peer Review
Ethical policies
Funding
Complaints and appeals
Open access and licensing
Authors
Sponsorship
Contact
Publish
Close Publish
Open Publish
Instructions to authors
Online submission
Home
Journal Information
Editorial Board
Operations Manual
Editorial Polices
Code of conduct for authors
Code of conduct for reviewers
Ahead of print
Read
Archive
Toc Alert
Current issue
Information
Editorial & Peer review
Ethical policies
Funding
Procedure for complaints and/or appeals
Open access & Licensing
Authors
Sponsors
Contact
Publish
Authors Instructions
Online submission
Home
Journal Information
Editorial Board
Operations Manual
Editorial Polices
Code of conduct for authors
Code of conduct for reviewers
Ahead of print
Read
Archive
Toc Alert
Current issue
Information
Editorial & Peer review
Ethical policies
Funding
Procedure for complaints and/or appeals
Open access & Licensing
Authors
Sponsors
Contact
Publish
Authors Instructions
Online submission
ES
EN
0,00
€
0
Cart
TOC Alert
Eva Poveda
The START Trial: Definitive Evidence to Treat All HIV-Positive Persons Regardless of CD4 Counts
News on HIV-HCV Coinfection: Update From the 2015 GEHEP Conference
Enfuvirtide, the First Fusion Inhibitor to Treat HIV Infection
Genotypic Determination of HIV Tropism – Clinical and Methodological Recommendations to Guide the Therapeutic Use of CCR5 Antagonists
Discovery of a Natural Defense Against HIV With Therapeutic Potential
HIV/AIDS in Sierra Leone: Characterizing the Hidden Epidemic
News on Viral Hepatitis in HIV: Update from the 2016 GEHEP Conference
Discovery of VIRIP – a Natural HIV Entry Inhibitor
Update on Clinical and Methodological Recommendations for Genotypic Determination of HIV tropism to Guide the Usage of CCR5 Antagonists
Multi-Step Inhibition against HIV Lifecycle-Underlying the âMagicâ? of Protease Inhibitors